Problematic issues of autoimmune hepatitis in children
Keywords:autoimmune hepatitis, children, diagnosis
Recently, autoimmune hepatitis (AIH) is beco-ming more common; as stated in the EASL 2015 recommendation, it can occur in any population and in all age groups. The etiology of AIH is unknown, the pathogenesis is insufficiently studied. Factors that directly trigger the autoimmune process have not been established. They can belong to environmental and infectious agents. Autoimmune hepatitis is heterogeneous in both clinical and serological manifestations, is characterized by a wide range of clinical symptoms of the disease: from asymptomatic to severe course, with or without extrahepatic manifestations, which can affect almost all organs and systems. AIH has a variety of clinical manifestations, it is not a clinically stable process, it should be excluded in all patients with symptoms of liver damage. Own observations of children with AIH with atypical manifestations of the disease are presented. Positive autoantibodies and the use of a pediatric scale are the keys in AIH diagnosis. With the exception of the fulminant course of the disease, AIH responds well to immunosuppressive therapy regardless of the degree of liver dysfunction. In childhood, remission is achieved in 60–90 % of patients depending on the severity of the disease at its manifestation, speed and degree of response to treatment.
European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J. Hepatol. 2015. 63(4). 9711004. DOI: 10.1016/j.jhep.2015.06.030.
JiménezRivera C., Ling S.C., Ahmed N., Yap J., Aglipay M., Barrowman N. et al. Incidence and Characteristics of Autoimmune Hepatitis Pediatrics. 2015. 136(5). e123748. DOI: 10.1542/peds.20150578.
MieliVergani G., Vergani D. Budesonide for juvenile auto immune hepatitis? Not yet. J. Pediatr. 2013. 163(5). 12468. DOI: 10.1016/j.jpeds.2013.06.064.
Gronbaek L., Vilstrup H., Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registrybased cohort study. J. Hepatol. 2014. 60(3). 6127. DOI: 10.1016/j. jhep.2013.10.020.
Ramachandran J., Sajith K.G., Pal S., Rasak J.V., Prakash J.A., Ramakrishna B. Clinicopathological profile and management of severe autoimmune hepatitis. Trop. Gastroenterol. 2014. 35. 2531. PMID: 25276903.
Di Giorgio A., Bravi M., Bonanomi E., Alessio G., Sonzogni A., Zen Y., Colledan M., D’Antiga L. Fulminant hepatic failure of autoimmune aetiology in children. J. Pediatr. Gastroenterol. Nutr. 2015. 60(2). 15964. DOI 10.1097/MPG.0000000000000593.
Anania C., De Luca E., De Castro G., Chiesa C., Pacifico L. Liver involvement in pediatric celiac disease. World J. Gastroenterol. 2015. 21(19). 581322. DOI: 10.3748/ wjg.v21.i19.5813.
de Boer Y.S., van Nieuwkerk C.M., Witte B.I., Mulder C.J., Bouma G., Bloemena E. Assessment of the histopathological key features in autoimmune hepatitis. Histopathology. 2015. 66(3). 35162. DOI: 10.1111/his.12558.
Miao Q., Bian Z., Tang R., Zhang H., Wang Q., Huang S., Xiao X., Shen L., Qiu D., Krawitt E.L., Gershwin M.E., Ma X. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin. Rev. Allergy Immunol. 2015. 48(2–3). 22635. DOI 10.1007/s1201601484320.
Tucker S.M., Jonas M.M., PerezAtayde A.R. Hyaline droplets in Kupffer cells: a novel diagnostic clue for autoimmune hepatitis. Am. J. Surg. Pathol. 2015. 39(6). 7728. DOI: 10.1097/PAS.0000000000000395.
Villalta D., Girolami E., Alessio M.G. et al. Autoantibody Profiling in a Cohort of Pediatric and Adult Patients With Autoimmune Hepatitis. J. Clin. Lab. Anal. 2016. 30. 41.
MieliVergani G., Vergani D., Baumann U., Czubkowski P., Debray D., Dezsofi A. et al. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. Journal of Pediatric Gastroenterology and Nutrition. 2018 Feb. 66(2). 1. Р. 345360. DOI: 10.1097/MPG.0000000000001801.
Mackay I.R. Autoimmune hepatitis: what must be said. Exp. Mol. Pathol. 2012. Vol. 93. P. 350353.
Gregorio G.V., McFarlane B., Bracken P., Vergani D., MieliVergani G. Organ and nonorgan specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity. 2002. 35. 515519.
Anand L., Choudhury A., Bihari C. et al. Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy. Hepatology. 2019. 70. 587.
Mack C.L., Adams D., Assis D.N. et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020. 72. 671.
Van Gerven N.M., de Boer Y.S., Mulder C.J., van Nieuwkerk C.M. et al. Autoimmune hepatitis. World J. Gastroenterol. 2016. Vol. 22. № 19. P. 46514661.
Wang Q., Yang F., Miao Q. et al. The clinical phenotypes of autoimmune hepatitis: A comprehensive review. J. Autoimmun. 2016. 66. 98.
Manns M.P., Lohse A.W., Vergani D. Autoimmune hepatitis — Update 2015. J. Hepatol. 2015. 62. S100.
Liberal R., Grant C.R. Cirrhosis and autoimmune liver disease: current understanding. World J. Hepatol. 2016. 8(28). 115768. DOI: 10.4254/wjh.v8.i28.1157.
D’Agostino D., Costaguta A., Alvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. Pediatrics. 2013. 132. e52630. DOI: 10.1542/peds.20111900.
Floreani A., Libera R., Vergani D., MieliVergani G. Autoimmune hepatitis: contrasts and comparisons in children and adults — a comprehensive review. J. Autoimmun. 2013. 46. 716. DOI: 10.1016/j.jaut.2013.08.004.
Kumari N., Kathuria R., Srivastav A., Krishnani N., Podda U., Yachha S.K. Significance of histopathological features in differentiating autoimmune liver disease from nonautoimmune chronic liver disease in children. Eur. J. Gastroenterol Hepatol. 2013. 25. 3337. DOI: 10.1097/MEG.0b013e32835a68a1.
Czaja A.J. Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I. Inflamm. Allergy Drug Targets. 2012. 11(5). 33750.
de Boer Y.S., Gerussi A., van den Brand F.F. et al. Association Between Black Race and Presentation and LiverRelated Outcomes of Patients With Autoimmune Hepatitis. Clin. Gastroenterol. Hepatol. 2019. 17. 1616.
Kerkar N., Czaja A.J., Mack C.L., Adams D., Assis D.N., Manns M.P., Mayo M.J., Nayfeh T., Majzoub A.M.M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and MetaAnalyses Supporting American Association for the Study of Liver Diseases Guidelines Hepatology. 2020. Vol. 72. Іssue 2. Р. 753769. https://doi.org/10.1002/hep.31407.
Noguchi F., Chu P.S., Taniki N., Yoshida A., Morikawa R., Yamaguchi A., Ikura A., Yamataka К., Hoshi H., Usui Sh., Ebinuma H., Saito H., Kanai T., Nakamoto N. Longterm Observation of Cyclosporine as Secondline Therapy in Adults of Severe Acute Autoimmune Hepatitis. 17 October 2020. Wiley Online Library. https://doi.org/10.1002/hep.31597.
Copyright (c) 2020 ACTUAL INFECTOLOGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.